← All trials
NCT04662528
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2021
- Primary completion
- Aug 31, 2022
- Completion date
- Oct 31, 2022
- First posted
- Dec 10, 2020
- Last posted
- Sep 16, 2021
- Enrollment
- —
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Matinas Biopharma, IncLead sponsor
- CovanceCollaborator
- Matinas Biopharma, IncStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.